Abstract:The authors regret that an error was made in the detail for affiliation c. The correct affiliation is: Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. The authors would like to apologise for any inconvenience caused. Re: Pathologic complete responses, long-term outcomes, and recurrence patterns in HER2-low vs. HER2-zero breast cancer after neoadjuvant chemotherapy: Several issues about HER2 expression and neoadjuvant chemotherapy in breast cancerEuropean Journal of CancerVol. 180PreviewWe followed with interest the report by Sora Kang et al. that pathological complete response (pCR) rate and disease-free survival (DFS) in patients with HER2-low as well as HER2-0 breast cancers who have undergone neoadjuvant chemotherapy [1]. There are many complex factors influencing condition of response and survival of breast cancer after neoadjuvant therapy by the changes of HER2 and hormone receptor (HR) status. We appreciated the authors' work in comparing the prognosis of patients with breast cancer after neoadjuvant chemotherapy in different HER2 status and providing new therapeutic ideas. Full-Text PDF

Corrigendum to "re: Pathologic Complete Responses, Long-Term Outcomes, and Recurrence Patterns in HER2-low Vs. HER2-zero Breast Cancer after Neoadjuvant Chemotherapy: Several Issues about HER2 Expression and Neoadjuvant Chemotherapy in Breast Cancer" [eur J Cancer 180 (2023) 184-185].